Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society´s Annual Meeting

NEW BRUNSWICK, N.J., May. 07 /PRNewswire/ --

NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.

A pre-recorded Webcast, with the lead tapentadol researchers, will be made available concurrent to the data presentations being made during the poster session at APS. Pre-registration is not required to view the webcast/podcast.

The presentation will provide an overview on tapentadol IR and review data from the following clinical posters:

-- Efficacy of Tapentadol Immediate Release in Patients With Pain After Bunionectomy -- Analgesic Efficacy of Tapentadol Immediate Release in Patients With Pain From End-Stage Joint Disease -- Tapentadol Immediate Release is Associated With Improved Gastrointestinal Tolerability Compared With Oxycodone Immediate Release Over 90 Days in Patients With Lower Back or Osteoarthritis Pain

The webcast/podcast and replay can be accessed by clicking on "Webcasts/Presentations" in the Investor Relations section of the Company's website at http://www.jnj.com.